<?xml version="1.0" encoding="UTF-8"?>
<p>Dyspepsia was the most common adverse event reported in both groups: 23 patients (23%) in the THF-6 group and 28 (28%) in the diclofenac group (relative risk = 0.821, 95% CI = 0.510 to 1.323, 
 <italic>p</italic>=0.417). Overall, the proportion of patients reporting any adverse events in the safety population was fairly similar between the two groups (
 <xref rid="tab3" ref-type="table">Table 3</xref>). All the adverse events reported were mild to moderate in intensity. Adverse events led to the premature discontinuation of 14 patients in the THF-6 group and 12 patients in the diclofenac group (
 <italic>χ</italic>
 <sup>2</sup> (1, 
 <italic>n</italic> = 200) = 0.177, 
 <italic>p</italic>=0.674). Gastrointestinal intolerance was the major reason for discontinuation of therapy (9 in the THF-6 group vs. 6 in the diclofenac group, 
 <italic>χ</italic>
 <sup>2</sup> (1, 
 <italic>n</italic> = 200) = 0.649, 
 <italic>p</italic>=0.421). During the trial, there was only one serious adverse event, hospitalization due to pesticide exposure, which was judged as definitely unrelated to the study drug.
</p>
